Satellos Bioscience (TSE:MSCL)
TSX:MSCL
Want to see TSE:MSCL full AI Analyst Report?
Top Page
Satellos Bioscience
(TSX:MSCL)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$11.50
▼(-3.77% Downside)
Action:ReiteratedDate:04/18/26
The score is mainly held back by weak financial performance (no revenue, ongoing losses, and sustained cash burn), only partly offset by a debt-free balance sheet. Technicals are mixed with negative MACD despite the price holding above several key moving averages, and valuation is constrained by a negative P/E and no dividend.
Positive Factors
Debt-free capital structure
A debt-free balance sheet materially reduces fixed financing costs and bankruptcy risk, preserving flexibility to fund R&D or restructure programs. Over a multi-month horizon this lowers cash outflows for interest and expands strategic options for partnering or staged financing.
Negative Factors
No revenue; persistent losses
The absence of revenue and ongoing operating losses indicate the company remains pre-commercial and reliant on external funding. Over months this limits internal funding options, creates dependency on capital markets or partnerships, and increases execution risk before cash-generating products exist.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free capital structure
A debt-free balance sheet materially reduces fixed financing costs and bankruptcy risk, preserving flexibility to fund R&D or restructure programs. Over a multi-month horizon this lowers cash outflows for interest and expands strategic options for partnering or staged financing.
Read all positive factors
Satellos Bioscience (MSCL) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$210.40M
Dividend YieldN/A
Average Volume (3M)178.54K
Price to Earnings (P/E)―
Beta (1Y)1.10
Revenue GrowthN/A
EPS Growth27.53%
CountryCA
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.69
Shares Outstanding20,831,190
10 Day Avg. Volume239,110
30 Day Avg. Volume178,539
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)4.17
Price to Sales (P/S)0.00
P/FCF Ratio-4.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$29.80Price Target Upside149.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.15
Revenue Forecast (FY)N/A
Satellos Bioscience Business Overview & Revenue Model
Company Description
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system whic...
How the Company Makes Money
null...
Satellos Bioscience Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
33
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -5.09K | -20.00K | -8.82M | -3.73M | -119.92K |
| EBITDA | -26.92M | -28.08M | -15.71M | -8.09M | -4.60M |
| Net Income | -25.31M | -28.10M | -15.89M | -11.32M | -15.51M |
Balance Sheet | |||||
| Total Assets | 31.83M | 73.02M | 44.30M | 6.20M | 12.59M |
| Cash, Cash Equivalents and Short-Term Investments | 27.66M | 69.85M | 39.59M | 1.92M | 4.87M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 4.10M | 5.16M | 3.62M | 2.83M | 2.10M |
| Stockholders Equity | 27.73M | 67.86M | 40.67M | 3.37M | 10.48M |
Cash Flow | |||||
| Free Cash Flow | -24.02M | -24.98M | -14.52M | -5.79M | -5.04M |
| Operating Cash Flow | -24.01M | -24.98M | -14.50M | -5.78M | -5.03M |
| Investing Cash Flow | -9.58M | 6.34M | -17.54M | -3.00K | 1.74M |
| Financing Cash Flow | 2.28M | 53.48M | 51.03M | 2.77M | 7.45M |
Satellos Bioscience Technical Analysis
Positive
11.95
Price Trends
12.67
Negative
11.31
Positive
9.63
Positive
Market Momentum
-0.56
Negative
60.78
Neutral
90.36
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MSCL, the sentiment is Positive. The current price of 11.95 is above the 20-day moving average (MA) of 9.29, below the 50-day MA of 12.67, and above the 200-day MA of 9.63, indicating a neutral trend. The MACD of -0.56 indicates Negative momentum. The RSI at 60.78 is Neutral, neither overbought nor oversold. The STOCH value of 90.36 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MSCL.
Satellos Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | C$210.40M | -4.57 | -51.42% | ― | ― | 27.53% | |
46 Neutral | C$151.99M | -55.85 | -66.34% | ― | ― | 59.00% | |
42 Neutral | C$40.55M | -4.40 | -103.51% | ― | ― | 54.74% | |
39 Underperform | C$32.27M | -12.93 | 72.34% | ― | ― | 10.49% |
* Healthcare Sector Average
TSE:MSCL
Satellos Bioscience
11.91
4.23
55.08%
TSE:ARCH
Arch Biopartners
0.46
-1.28
-73.56%
TSE:MDNA
Medicenna Therapeutics Corp
0.61
-0.45
-42.45%
TSE:HBP
Helix BioPharma
1.99
1.21
155.13%
TSE:METX
ME Therapeutics Holdings, Inc.
2.50
-6.50
-72.22%
TSE:ONCO
Onco-Innovations Ltd.
1.47
0.07
5.00%
Satellos Bioscience Corporate Events
Business Operations and Strategy
Satellos to Highlight Duchenne Drug Program at Series of Investor Conferences
Positive
Feb 17, 2026
Satellos Bioscience said its management team will present at several high-profile healthcare investor conferences in late February and early March, including events hosted by Oppenheimer, TD Cowen and Leerink Partners, with presentations accessibl...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and Financing
Satellos Raises US$50 Million in Cross-Border Offering as Shares Debut on Nasdaq
Positive
Feb 6, 2026
Satellos Bioscience has priced a cross-border public offering of approximately US$50 million in common shares and pre-funded warrants in Canada and the United States, with 4,455,445 common shares and 495,049 pre-funded warrants to be sold, and an ...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Satellos Plans Cross-Border Share Offering and Nasdaq Listing to Fund Muscle Disease Pipeline
Positive
Feb 5, 2026
Satellos Bioscience has filed a preliminary prospectus supplement in Canada and the U.S. for a proposed public offering of common shares or pre-funded warrants, and has applied to list its shares on the Nasdaq Global Market under the ticker symbol...
Business Operations and StrategyExecutive/Board Changes
Satellos Strengthens Executive Bench With Veteran Regulator as Duchenne Program Advances
Positive
Jan 29, 2026
Satellos Bioscience has appointed industry veteran Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs, bringing in a leader with a strong track record in steering breakthrough therapies such as Vertex’s cystic fibro...
Business Operations and StrategyDelistings and Listing ChangesStock Split
Satellos Consolidates Shares Ahead of Proposed Nasdaq Listing
Positive
Jan 28, 2026
Satellos Bioscience has completed a one-for-12 consolidation of its common shares, reducing the number of outstanding shares from about 185.5 million to roughly 15.5 million, as part of its effort to meet the share price and other requirements for...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.